Abstract:Background According to prescribing information for Myrtol standardized enteric-coated soft capsules, the medicine should be taken on an empty stomach. Some patients may experience stomach discomfort after oral administration in fasted state and would prefer to take the medicine after a meal. However, there is no literature addressing the effect of meal on absorption of this drug; therefore, it is desirable to explore the feasibility of taking the capsule after a meal from pharmacokinetic perspective. Methods A gas chromatography coupled with triple quadruples mass spectrometry assay was established and validated for determining plasma concentrations of eucalyptol, a target component of Myrtol standardized capsules. A self-control clinical study was carried out in healthy male volunteers in fasted and fed states after a single oral dose of 300 mg capsules. Comparison of pharmacokinetic parameters in the two phases and bioequivalence evaluation were performed. Results The specificity, sensitivity, accuracy, and precision of the assay satisfied the requirements for biopharmaceutical analysis. Pharmacokinetic parameters of eucalyptol (fasted vs fed) were as follows: maximal plasma concentrations (Cmax) (167.60±114.69 vs 518.89±314.47 ng·mL−1), time of maximum concentration (Tmax) (3.7±1.1 vs 4.8±0.7 h), elimination half-life (T1/2) (3.2±1.4 vs 2.6±0.7 h), area under the plasma concentration–time curve (AUC0–t) (584.91±369.90 vs 1,271.61±605.82 ng·h·mL−1), and AUC0–∞ (690.36±467.26 vs 1,458.02±720.21 ng·h·mL−1). There was statistically significant difference in Cmax, AUC0–t, and AUC0–∞ between the two dosing methods (P<0.05). Pharmacokinetic parameters of eucalyptol given in fasted state in Chinese were comparable to those in Germany population. The 90% confidence intervals for the ratio of Cmax (18.4%~64.7%), AUC0–t (28.9%~68.5%), and AUC0–∞ (31.1%~68.4%) values for the test (fasted) and reference (fed) were beyond the Food and Drug Administration’s acceptable range of 80%~125%. In addition, significant difference was obtained in Tmax (P<0.05). Conclusion Compared with dosing at fasted state, taking Myrtol standardized capsules after a meal achieves a delayed absorption rate and an increased absorption extent. The two dosing methods were not bioequivalent in this small study and, thus, not interchangeable. Patient preference and pharmacokinetic food–drug interaction issue should be balanced. Further clinical study is necessary to explore the clinical outcome of oral administration of Myrtol standardized capsules after or with meal.

Study on Pharmacokinetic Interaction Between Roxithromycin and Ambroxol in Human

Pharmacokinetics and Bioequivalance of Ambroxol Dispersible Tablets in Healthy Volunteers

Pharmacokinetic And Bioequivalence Study Of Three Oral Formulations Of Ambroxol 30 Mg: A Randomized, Three-Period Crossover Comparison In Healthy Volunteers

Is It Appropriate Regarding Patient Preference to Take Myrtol Standardized Enteric-Coated Soft Capsules after a Meal Rather Than at Fasted State? A Food–drug Pharmacokinetic Interaction Study in Healthy Chinese Volunteers

Clinical effect of large dose of ambroxol in treatment of acute episode of chronic bronchitis (AECB)

Pharmacokinetics and bioequivalence of roxithromycin capsules in healthy volunteers

Studies on Bioequivalence of Ramipril Capsule in Healthy Volunteers

Study on Bioequivalence of Ambroxol Hydrochloride Tablets from Domestic and Import

Study on Pharmacokinetic Interaction of Doxofylline and Moxifloxacin in Rats

Efficacy and Safety of Roxithromycin/ambroxol Dispersible Tablets in Patients with Acute Bacterial Lower Respiratory Tract Infection

Population Pharmacokinetics of Ambroxol Hydrochloride in Chinese Healthy Male Subjects

Efficacy and safety of roxithromycin/ambroxol in patients with lower respiratory tract infection

Pharmacokinetics of Moxifloxacin Hydrochloride Tablets in Healthy Volunteers

Bioequivalence of Clarithromycin Dispersed Tablet in Health Volunteers

Clinical Study of Inhaled Ambroxol in the Adjunctive Treatment of Lower Respiratory Tract Infection Induced by Pseudomonas Aeruginosa

Design study of pharmacokinetics and comparison of 4 kinds of the clinal trial phase Ⅱ design of roxithromycin/ambroxol hydrochloride compound tablets

Simultaneous determination of amoxicillin and ambroxol in human plasma by LC-MS/MS: validation and application to pharmacokinetic study

A Multicenter Randomized Controlled Clinical Trials of Ambroxol Hydrochloride Injection in Adjuvant Treatment of Respiratory Diseases

Effects of Food on Absorption of Ozagrel after Oral Administration in Healthy Volunteers

Pharmacokinetics and Bioequivalence of 2 Kinds of Amoxicillin Dispersible Tablets in Healthy Volunteers

Evaluation of safety and efficacy of inhaled ambroxol in hospitalized adult patients with mucopurulent sputum and expectoration difficulty